MiNK Therapeutics, Inc.
INKTMiNK Therapeutics, Inc. in brief
MiNK Therapeutics, Inc. is a listed company in the Biotechnology industry, based in New York, New York, USA. Its market value was $55 M on 30 October 2026, which makes it the 20,983rd largest listed company in the world and the 3,822nd largest in the USA on this site. It employs about 15 people and Jennifer Buell is its chief executive. Its shares trade under the symbol INKT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. is focused on developing innovative treatments for cancer and immune-mediated diseases using allogeneic, ex-vivo expanded invariant natural killer T cells. Amid a broader industry renaissance in innate immunity—highlighted by surging investment and clinical activity in NK, γδ T, and iNKT-based therapies—iNKT cells represent a distinct T cell population that uniquely bridges innate and adaptive immunity. They combine durable memory responses characteristic of adaptive T cells with rapid, MHC-independent rapid cytolytic capabilities of natural killer cells. This dual functionality enables direct tumor killing via CD1d and stress ligands, potent orchestration of the tumor microenvironment through activation of dendritic cells and NK cells, elimination of immunosuppressive myeloid populations, and restoration of exhausted T-cell function—all while naturally suppressing graft-versus-host disease. This unique combination positions iNKT cells as an optimal platform for allogeneic therapy, given their natural homing capabilities, tumor clearance potential, and efficacy against infected cells.
From the company's annual report filed with the US SEC: read the report
MiNK Therapeutics, Inc. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed MiNK Therapeutics, Inc.Formerly AgenTus Therapeutics, Inc..
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 15 October 2021; shares registered for exchange trading on 13 October 2021.
Events of MiNK Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,185 (Jan 2022) · #4,469 (Dec 2022) · #4,611 (Jul 2023) · #4,170 (Jan 2024) · #1,972 (Mar 2026) · #3,698 (Aug 2026) · #3,787 (Oct 2026) · #3,826 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- -28.8%
- Net margin
- —
- Operating margin
- —
- Return on equity
- —
- Liabilities / assets
- 199.9%
- Profit per employee
- $-833 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-13M | $-12M | — |
| Dec 2024 | — | — | $-11M | $-11M | — |
| Dec 2023 | — | — | $-23M | $-22M | — |
| Dec 2022 | — | — | $-31M | $-28M | — |
| Dec 2021 | — | — | $-28M | $-30M | — |
| Dec 2020 | — | — | $-15M | $-16M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-6M | — | — | $-2.93 | — |
| Dec 2024 | $-10M | — | — | $-2.86 | — |
| Dec 2023 | $-16M | $0M | $-16M | $-6.54 | — |
| Dec 2022 | $-19M | $0M | $-19M | $-0.83 | — |
| Dec 2021 | $-13M | $0M | $-13M | $-1.16 | — |
| Dec 2020 | $-8M | $0M | $-8M | $-0.67 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jun 23, 20268-KCurrent reportShareholder vote
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 15, 20268-KCurrent reportResults of operations
- Apr 30, 2026DEF 14AProxy statement
- Mar 31, 202610-KAnnual report · period to Dec 2025
- Mar 31, 20268-KCurrent reportResults of operations
- Mar 27, 20268-KCurrent reportOther events
- Mar 19, 20268-KCurrent reportDirectors or officers changed
Official filings of MiNK Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-13 M
- Net income
- $-12 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $14 M
- Total liabilities
- $28 M
- Total equity
- $-14 M
As of December-2025
Top 26 institutional investors in MiNK Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 68,452 | -208 (-0.30%) | 1.33% | $1 M | Nov 13, 2026 |
| 2 | DNB Asset Management As | 43,960 | -11,182 (-20.28%) | 0.86% | $1 M | Nov 12, 2026 |
| 3 | Geode Capital Management, LLC | 18,759 | +3,186 (+20.46%) | 0.37% | $0 M | Nov 6, 2026 |
| 4 | Longbow Finance SA | 16,667 | 0 (0.00%) | 0.32% | $0 M | Nov 13, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 13,164 | +4,877 (+58.85%) | 0.26% | $0 M | Nov 13, 2026 |
| 6 | BlackRock, Inc. | 13,074 | -308 (-2.30%) | 0.25% | $0 M | Nov 13, 2026 |
| 7 | Bolton Securities Corporation | 13,000 | 0 (0.00%) | 0.25% | $0 M | Nov 12, 2026 |
| 8 | Steward Partners Investment Advisory, LLC | 2,000 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 9 | US Bancorp \de\ | 1,995 | 0 (0.00%) | 0.04% | $0 M | Nov 5, 2026 |
| 10 | UBS Group AG | 1,462 | -3,423 (-70.07%) | 0.03% | $0 M | Nov 10, 2026 |
| 11 | Federation des caisses Desjardins du Quebec | 750 | +250 (+50.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 12 | Paladin Partners, LLC | 500 | -500 (-50.00%) | 0.01% | $0 M | Oct 6, 2026 |
| 13 | Tower Research Capital LLC (TRC) | 303 | -119 (-28.20%) | 0.01% | $0 M | Nov 16, 2026 |
| 14 | Covestor Ltd | 119 | 0 (0.00%) | 0.00% | $0 M | Oct 30, 2026 |
| 15 | Morgan Stanley | 118 | +5 (+4.42%) | 0.00% | $0 M | Nov 13, 2026 |
| 16 | Osaic Holdings, Inc. | 117 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 17 | Royal Bank Of Canada | 72 | New | 0.00% | $0 M | Nov 16, 2026 |
| 18 | Wells Fargo & Company/mn | 26 | +24 (+1200.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 19 | Northwestern Mutual Wealth Management Co | 18 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 20 | Caitong International Asset Management Co., Ltd | 18 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 21 | Game Plan Financial Advisors, LLC | 16 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 22 | Clearstead Advisors, LLC | 14 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 23 | BNP Paribas Financial Markets | 13 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 24 | Jpmorgan Chase & Co | 9 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 25 | Key Financial Inc | 4 | 0 (0.00%) | 0.00% | $0 M | Nov 2, 2026 |
Show all 26: investors 26 to 26
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Jones Financial Companies Lllp | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding MiNK Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 53,070 | $1 M | 1.0% | <0.01% | +7.7% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 15,382 | $0 M | 0.30% | <0.01% | +53% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 6,599 | $0 M | 0.13% | <0.01% | −0.9% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 6,734 | $0 M | 0.13% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 1,902 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 1,883 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,389 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 445 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 208 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at MiNK Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jennifer BuellChief Executive Officer, Director | Sell | -6,938 | $10.56 | $73 K | 74,195 | Form 4 |
| filed | Jennifer BuellChief Executive Officer, Director | Option exercise | +23,191 | — | — | 81,133 | Form 4 |
| filed | Ulf WiinbergDirector | Grant or award | +1,279 | $10.95 | $14 K | 23,929 | Form 4 |
| filed | Barbara RyanDirector | Grant or award | +1,622 | $10.95 | $18 K | 23,591 | Form 4 |
| filed | Peter BehnerDirector | Grant or award | +1,485 | $10.95 | $16 K | 24,404 | Form 4 |
| filed | Brian CorveseDirector | Grant or award | +1,633 | $10.95 | $18 K | 54,770 | Form 4 |
| filed | John Bradley HolcombDirector | Grant or award | +1,233 | $10.95 | $14 K | 4,691 | Form 4 |
| filed | Barbara RyanDirector | Sell | -500 | $12.68 | $6 K | 22,969 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: MiNK Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split ; 2.783-for-1 split
Trading halts
- 2025-07-11 14:41 UTC, code LUDP, resumed 14:46 UTC
- 2025-07-11 14:13 UTC, code LUDP, resumed 14:18 UTC
- 2025-07-11 14:01 UTC, code LUDP, resumed 14:06 UTC
- 2025-07-11 13:46 UTC, code LUDP, resumed 13:51 UTC
- 2025-07-11 13:34 UTC, code LUDP, resumed 13:44 UTC
Fails to deliver
- : 8 shares at $10.69
- : 2,025 shares at $10.95
- : 2,190 shares at $10.71
- : 935 shares at $10.62
- : 112 shares at $9.41
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
MiNK Therapeutics, Inc. scorecard#
Passes 2 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-28.8%Free cash flow is -28.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.93 vs -2.86Diluted EPS -2.93 in fiscal 2025 against -2.86 the year before (report's currency).
- ✓Net income higher than five years earlier-$12 M-$12 M in fiscal 2025 against -$16 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$12 MNet income -$12 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.06 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year13.2%Diluted shares up 13.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
MiNK Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 5.8−9.1%— | 6.3−59.1%— | 15−33.0%— | 23+65.5%— | 14+46.9%— | 9.5—— | |
| General and administrative | 6.7+56.0%— | 4.3−41.9%— | 7.4−5.1%— | 7.8+68.8%— | 4.6+260%— | 1.3—— | |
| Operating income | −13—— | −11—— | −23—— | −31—— | −28—— | −15—— | |
| Interest expense and finance costs | −0.1—— | −0.1—— | −0.0—— | — | 2.4−0.4%— | 2.4—— | |
| Net interest income | 0.2+4.4%— | 0.2−62.7%— | 0.5+82.9%— | 0.3—— | −2.4—— | — | |
| Other non-operating income (expense) | −0.0−110%— | 0.3—— | −0.0−100%— | 2.7+1119%— | 0.2−73.6%— | 0.8—— | |
| Net income including minority interests | −12—— | −11—— | −22—— | −28—— | −30—— | −16—— | |
| Net income attributable to shareholders | −12—— | −11—— | −22—— | −28—— | −30—— | −16—— | |
| Earnings per share, basic | -2.93—— | -2.86—— | -6.54r-0.65—— | -0.83—— | -1.16—— | -0.67—— | |
| Earnings per share, diluted | -2.93—— | -2.86—— | -6.54r-0.65—— | -0.83—— | -1.16—— | -0.67—— | |
| Shares, weighted average (basic) | 4.3+13.2%— | 3.8+9.8%— | 3.4r34−89.8%— | 34+29.4%— | 26—— | — | |
| Shares, weighted average (diluted) | 4.3+13.2%— | 3.8+9.8%— | 3.4r34−89.8%— | 34+29.4%— | 26+8.0%— | 24—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 13+192%93.8% | 4.6+35.9%80.0% | 3.4−82.9%74.0% | 20−49.5%91.4% | 39+1345%96.6% | 2.7—59.1% | |
| Other current assets | 0.2+28.6%1.5% | 0.2−7.7%2.9% | 0.2−62.2%3.9% | 0.5−36.8%2.2% | 0.7−18.5%1.8% | 0.9—20.1% | |
| Current assets | 14+178%97.3% | 5.0+38.6%87.2% | 3.6−82.4%79.0% | 20−48.5%95.0% | 40+867%98.5% | 4.1—89.9% | |
| Property, plant and equipment | 0.4−46.7%2.7% | 0.7−23.2%12.8% | 1.0−10.6%21.0% | 1.1+75.9%5.0% | 0.6+32.3%1.5% | 0.5—10.1% | |
| Total assets | 14+149%100% | 5.7+25.7%100% | 4.6−78.8%100% | 21−46.6%100% | 40+783%100% | 4.6—100% | |
| Accounts payable | 3.4+25.6%24.1% | 2.7−30.3%47.7% | 3.9−32.8%85.9% | 5.8+94.4%27.1% | 3.0−4.7%7.4% | 3.1—69.0% | |
| Current liabilities | 13+87.2%91.5% | 7.0−39.0%122% | 11−10.1%250% | 13−23.0%59.1% | 16+15.8%40.9% | 14r14—312% | |
| Retained earnings | −157—−1100% | −144—−2520% | −133—−2930% | −111—−517% | −83—−206% | −53—−1158% | |
| Shareholders' equity | −14—−99.9% | −20—−342% | −18—−397% | −0.4−102%−1.9% | 24—59.1% | −54r−54—−1183% | |
| Total liabilities and equity | 14+149%100% | 5.7+25.7%100% | 4.6−78.8%100% | 21−46.6%100% | 40+783%100% | 4.6—100% | |
| Shares outstanding | 4.7+18.8%— | 4.0+14.5%— | 3.5r35−89.8%— | 34+1.1%— | 33—— | — | |
| Cash-flow statement | |||||||
| Share-based compensation | 2.7+47.7%— | 1.8−53.1%— | 3.9+27.5%— | 3.0+73.5%— | 1.7+1887%— | 0.1—— | |
| Cash from operating activities | −5.9—— | −9.6—— | −16—— | −19—— | −13—— | −8.3—— | |
| Capital expenditure | — | — | −0.1—— | −0.3—— | −0.2—— | −0.1—— | |
| Cash from investing activities | — | — | −0.1—— | −0.3—— | −0.2—— | −0.1—— | |
| Debt issued | — | — | — | — | — | 0.4—— | |
| Cash from financing activities | 15+36.1%— | 11—— | −0.4—— | −0.2−100%— | 49+344%— | 11—— | |
| Exchange-rate effect on cash | −0.0—— | −0.1—— | −0.0−230%— | 0.0+14.7%— | 0.0—— | −0.3—— | |
| Change in cash | 8.8+626%— | 1.2—— | −16—— | −19−153%— | 36+1413%— | 2.4—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 0.2—100% | — | — | — | 0—— | — | — | — | — | — | — | — | |
| Research and development | 6.4+13.4%— | 1.8+57.8%902% | 1.9+2.6%— | 1.2−4.6%— | 1.5*+7.6%— | 1.1+111%— | 1.8−0.0%— | 1.3−50.5%— | 1.4*−57.5%— | 0.5—— | 1.8—— | 2.5—— | 3.3*—— | |
| General and administrative | 5.8+0.5%— | 1.0−44.0%517% | 1.3−28.1%— | 1.7+32.0%— | 1.8*+118%— | 1.8+58.8%— | 1.8+74.2%— | 1.3−0.7%— | 0.8*−63.1%— | 1.2—— | 1.1—— | 1.3—— | 2.2*—— | |
| Operating income | −11—— | −2.6—−1319% | −3.2—— | −2.9—— | −2.7*—— | −3.2—— | −4.1—— | −2.7—— | −2.5*—— | −1.9—— | −3.1—— | −3.8—— | −5.5*—— | |
| Interest expense and finance costs | — | −0.0—−0.5% | −0.0—— | −0.0—— | — | −0.0—— | −0.0—— | −0.0—— | — | −0.0—— | −0.0—— | −0.0—— | — | |
| Net interest income | 0.3+211%— | 0.1+31.1%36.2% | 0.1+20844%— | 0.1+498%— | 0.1*+181%— | 0.1−29.3%— | 0.0−99.1%— | 0.0−18.7%— | 0.0*−4.7%— | 0.1—— | 0.0—— | 0.0—— | 0.0*—— | |
| Other non-operating income (expense) | 0.1—— | 0.0−94.7%6.3% | 0.0—— | 0.1—— | −0.0*—— | 0.2—— | −0.2−156%— | −0.1—— | 0*—— | 0*—— | 0.3—— | — | −0.0*—— | |
| Net income including minority interests | −11—— | −2.6*—−1276% | −3.1*—— | −2.7—— | −2.6*—— | −2.9*—— | −4.2*—— | −2.8—— | −2.5*—— | −1.8*—— | −2.7*—— | −3.8—— | −5.5*—— | |
| Net income attributable to shareholders | −11—— | −2.6—−1276% | −3.1—— | −2.7—— | −2.6*—— | −2.9—— | −4.2—— | −2.8—— | −2.5*—— | −1.8—— | −2.7—— | −3.8—— | −5.5*—— | |
| Earnings per share, basic | — | -0.50—— | -0.62—— | -0.57—— | — | -0.65—— | -1.06—— | -0.70—— | — | -0.46r-0.05—— | -0.73r-0.07—— | -1.10r-0.11—— | — | |
| Earnings per share, diluted | — | -0.50—— | -0.62—— | -0.57—— | — | -0.65—— | -1.06—— | -0.70—— | — | -0.46r-0.05—— | -0.73r-0.07—— | -1.10r-0.11—— | — | |
| Shares, weighted average (basic) | 5.1+14.8%— | 5.1+14.8%— | 5.0+26.2%— | 4.8+21.0%— | — | 4.4+12.4%— | 4.0+7.2%— | 4.0+14.5%— | — | 4.0r40—— | 3.7r37—— | 3.5r35—— | — | |
| Shares, weighted average (diluted) | 5.1+14.8%— | 5.1+14.8%— | 5.0+26.2%— | 4.8+21.0%— | — | 4.4+12.4%— | 4.0+7.2%— | 4.0+14.5%— | — | 4.0r40—— | 3.7r37—— | 3.5r35—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 7.5—90.6% | 7.5−21.4%90.6% | 8.8+424%91.6% | 9.5+194%91.8% | 13+192%93.8% | 9.5r14+50.1%63.5% | 1.7−81.9%67.7% | 3.2−44.4%75.8% | 4.6+35.9%80.0% | 6.3—85.8% | 9.3—90.2% | 5.8—84.4% | 3.4—74.0% | |
| Other current assets | 0.1—1.0% | 0.1+266000%1.0% | 0.2+284%2.2% | 0.2+114%2.2% | 0.2+28.6%1.5% | 0.0−99.7%0.0% | 0.1−9.7%2.2% | 0.1−11.2%2.5% | 0.2−7.7%2.9% | 0.0—0.2% | 0.1—0.6% | 0.1—1.8% | 0.2—3.9% | |
| Current assets | 7.9—95.9% | 7.9−45.6%95.9% | 9.3+362%96.7% | 10+180%96.6% | 14+178%97.3% | 15+121%97.1% | 2.0−78.8%81.0% | 3.6−40.3%83.9% | 5.0+38.6%87.2% | 6.6—89.2% | 9.5—91.8% | 6.0—87.0% | 3.6—79.0% | |
| Property, plant and equipment | 0.3—4.1% | 0.3−21.0%4.1% | 0.3−32.7%3.3% | 0.4−48.4%3.4% | 0.4−46.7%2.7% | 0.4−46.3%2.9% | 0.5−44.3%19.0% | 0.7−23.2%16.1% | 0.7−23.2%12.8% | 0.8—10.8% | 0.8—8.2% | 0.9—13.0% | 1.0—21.0% | |
| Total assets | 8.2—100% | 8.2−44.9%100% | 9.6+287%100% | 10+143%100% | 14+149%100% | 15+103%100% | 2.5−75.9%100% | 4.3−38.1%100% | 5.7+25.7%100% | 7.4—100% | 10—100% | 6.9—100% | 4.6—100% | |
| Accounts payable | 4.5—54.5% | 4.5+21.6%54.5% | 3.9+18.2%40.8% | 3.4+27.4%32.7% | 3.4+25.6%24.1% | 3.7+56.4%24.7% | 3.3+3.5%133% | 2.7−23.7%62.4% | 2.7−30.3%47.7% | 2.4—32.0% | 3.2—31.0% | 3.5—50.6% | 3.9—85.9% | |
| Current liabilities | 8.2—99.2% | 8.2−39.1%99.2% | 7.6−42.5%78.7% | 7.3−39.9%70.2% | 13+87.2%91.5% | 13+81.6%89.8% | 13+29.7%530% | 12+9.1%284% | 7.0−39.0%122% | 7.4—100% | 10—98.3% | 11—161% | 11—250% | |
| Retained earnings | −165—−2003% | −165—−2003% | −163—−1691% | −159—−1536% | −157—−1100% | −154—−1030% | −151—−6085% | −147—−3444% | −144—−2520% | −142—−1922% | −140—−1355% | −137—−1990% | −133—−2930% | |
| Shareholders' equity | −16—−197% | −16—−197% | −14—−146% | −13—−122% | −14—−99.9% | −14—−90.3% | −25—−1014% | −22—−511% | −20—−342% | −18—−238% | −17—−161% | −20—−294% | −18—−397% | |
| Total liabilities and equity | 8.2—100% | 8.2−44.9%100% | 9.6+287%100% | 10+143%100% | 14+149%100% | 15+103%100% | 2.5−75.9%100% | 4.3−38.1%100% | 5.7+25.7%100% | 7.4—100% | 10—100% | 6.9—100% | 4.6—100% | |
| Shares outstanding | 5.1—— | 5.1—— | 5.1—— | — | 4.7+18.8%— | — | — | — | 4.0+14.5%— | — | — | — | 3.5r35—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 2.0−21.9%— | 0.3−46.4%167% | 0.4−53.0%— | 0.6+6.6%— | 0.6*+45.1%— | 0.6−29.7%— | 0.9+6.3%— | 0.6−0.2%— | 0.4*−64.6%— | 0.9—— | 0.8—— | 0.6—— | 1.1*—— | |
| Cash from operating activities | −7.2—— | −1.3*—−638% | −2.1*—— | −1.7—— | −2.1*—— | −0.9*—— | −1.6*—— | −1.3—— | −1.7*—— | −3.0*—— | −2.3*—— | −2.5—— | −3.0*—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Cash from investing activities | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Cash from financing activities | 0.4−96.7%— | 0*−100%0.0% | 1.4*+252891%— | −2.1−364827%— | 1.2*—— | 14*+198955%— | 0.0*−100.0%— | 0.0−100.0%— | −0.0*—— | 0.0*—— | 5.8*—— | 5.0—— | −0.0*—— | |
| Exchange-rate effect on cash | −0.0—— | −0.0*—−1.9% | −0.0*−113%— | −0.0—— | −0.0*—— | −0.0*−287%— | 0.0*—— | −0.0—— | −0.0*−646%— | 0.0*—— | −0.0*—— | −0.0—— | 0.0*—— | |
| Change in cash | −6.8−186%— | −1.3*−111%−668% | −0.7*—— | −3.8—— | −0.9*—— | 13*—— | −1.6*−144%— | −1.3−155%— | −1.8*—— | −3.0*—— | 3.5*—— | 2.4—— | −3.0*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where MiNK Therapeutics, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at MiNK Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Directors and officers 5 · Material agreement 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
H-1B hiring at MiNK Therapeutics, Inc.#
2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $109 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Scientist IMolecular and Cellular Biologists | 1 | $120 K |
| Senior Research AssociateMolecular and Cellular Biologists | 1 | $98 K |
Where: Lexington, MA 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 2 | 2 | $109 K | 2 |
| FY2024 | 1 | 1 | $120 K | 1 |
| FY2023 | 1 | 1 | $98 K | 1 |
| FY2021 | 1 | 1 | $82 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as MiNK Therapeutics, Inc. and AgenTus Therapeutics, Inc.
How MiNK Therapeutics, Inc. compares in Biotechnology
- Market cap$55 M · higher than 28% of 726
- FCF yield-28.8% · higher than 35% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| MiNK Therapeutics, Inc.🇺🇸 | $55 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of February 28, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at MiNK Therapeutics, Inc.? Verify and update this profile — free
Show MiNK Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.